FM is characterized by chronic widespread pain and painful body pressure points (tender points).
Several researchers suggest that elevated levels of the pronociceptive substance substance P enhance pain experience (sensitization of ascending pain pathways). FM is often accompanied by several non-specific symptoms including fatigue, stiffness, disordered sleep, cognitive dysfunction, dysesthesia, psychological distress, headaches, and poor balance. These non-specific symptoms are also observed in ‘sickness behavior’ which is induced by infectious and inflammatory processes, characterized by cytokines. A literary search for cytokines in FM patients suggested several upregulated cytokine levels in FM patients, compared with controls. Furthermore, diseases that show overlap with FM are characterized by enhanced oxidative stress levels. Another literary search regarding oxidative stress in FM patients suggested upregulated oxidative stress levels in FM patients, compared with controls. Eventually, this thesis hypothesized that oxidative stress might be responsible for increased substance P levels via cytokine generation, resulting in elevated pain experience. To place this hypothesis in a broad perspective, the physiological effect of several associated co-morbidities (e.g. diabetes) have been analyzed.
Because FM symptoms appear to be caused by elevated cytokine- and oxidative stress-levels, inhibition of cytokine- and oxidative stress- levels as treatment should be examined.
Oxidative stress inhibition treatment
Injections with vitamin B12, which scavenges nitric oxide, showed alleviations of symptoms in FM patients, CFS patients and multiple complex syndrome patients. Furthermore, intra-muscular GSH injections showed positive results after 6 months of treatment; 82% of the patients experienced improvement in fatigue, 71% showed improvement in memory and concentration, and 62% experienced improvement in levels of pain. Finally, the administration of N-acetyl-cysteine, a strong anti-oxidant that supports GSH homeostasis, delays muscle fatigue in exercising humans.
In summary, it appears that non-pharmaceutical- and pharmaceutical-treatments based on cytokine- and oxidative stress- inhibition, have clinical effect in diseases that show overlap with FM.
M.S.C.E. Vorage (author): Clinical & Health Psychology, Utrecht, The Netherlands Master thesis of the University of Utrecht, the Netherlands
1) Bennett R.M.. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin N AM 2009;35;215-232.
2) Mease P.J. and Choy E.H.. Pharmacotherapy of Fibromyalgia Rheum Dis Clin N AM. 2009;35;359- 372.
3) Hassett A.L. and Gevirtz R.N. Nonpharmacologic treatment for fibromyalgia: Patient education, cognitive behavioural therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin N AM. 2009;35;393-407.
4) Russell I.J. and Larson A.A. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin N AM. 2009;35;421-435.
5) Carruthers and v.d. Sande. A clinical case definition and guidelines for medical practitioners. An overview of the Canadian Consensus document.
6) Nebel M.B. and Gracely R.H. Neuroimaging of fibromyalgia. Rheum Dis Clin N AM. 2009;35;313-327.
7) Choy E.H. and Mease P.J. Key symptom domains to be assessed in Fibromyalgia (outcome measures in rheumatoid Arthritis Clinical Trials. Rheum Dis Clin N AM. 2009;35;329- 337.
8) Williams D.A. and Schilling S. Advances in the assessment of Fibromyalgia. Rheum Dis Clin N AM. 2009;35;339-357.
9) Buskila D. Pediatric Fibromyalgia. Rheum Dis Clin N AM. 2009;35;253- 261.
10) Chung C.P. Oxidative stress in fibromyalgia and its relationship to symptoms. Clinical Rheumatology. 2009;28;435-438.
11) Altindag O. and Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox report.2006;11;131-135.
12) Wassmann S, Stumpf F.M., Strehlow K., Schmid A. , Schieffer B. , Böhm M. ,Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94;534-541.
13) Frossi B. , Carli de M., Daniel K.C., Rivera J., Pucillo C. Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. Eur J Immunol. 2003;33;2168-2177.
14) Haddad JJ. Redox regulation of pro-inflammatory cytokines and IkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem Biophys Res Commun. 2002;296;847- 856.
15) Seo JY, Kim H, Seo JT, Kim KH. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells: effects of small-molecule antioxidants. Pharmacology. 2002;64;63-70.
16) Zhang J, Johnston G, Stebler B, Keller ET. Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase. Antioxid Redox Signal. 2001;3;493-504.
17) Haddad JJ, Safieh-Garabedian B, Saadé NE, Kanaan SA, Land SC. Chemioxyexcitation (delta pO2/ROS)- dependent release of IL-1 beta, IL-6 and TNF-αlpha: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium. Cytokine. 2001;13;138-147.
18) Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr. 1999;23;1-6.
19) Gwinn MR, Vallyathan V. Respiratory Burst: Role in Signal Transduction in Alveolar Macrophages. Journal of toxicology and environmental health. 2006;9;27 – 39.
20) Fujishita K, Ozawa T, Shibata K, Tanabe S, Sato Y, Hisamoto M, Okuda T, Koizumi S. Grape seed extract acting on astrocytes reveals neuronal protection against oxidative stress via interleukin-6-mediated mechanisms. Cell Mol Neurobiol. 2009;8;1121- 1129.
21) Munoz J, Albillos A, Perez- Paramo M, Rossi I and Alvarez-Mon M. Factors mediating the hemodynamic effects of TNF-α in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol. 1999;276;687-693.
22) Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology. 2007;46;802- 812.
23) Kiraly MA, Campbell JE, Park E, Bates HE, Yue JT, Rao V, Matthews SG, Bikopoulos G, Rozakis-Adcock M, Giacca A, Vranic M, Riddell MC. Exercise maintaince euglycemia in association with decreased activation of c-Jun NH-2-terminal kinase and serine phosphorylation of IRS-1 in the liver of ZDF rats. Am J Physiol Endocrinol Metab. 2009;8;671-682.
24) Park EJ, Park K. Induction of oxidative stress and inflammatory cytokines by manganese chloride in cultured T98G cells, human brain glioblastoma cell line. Toxicol In Vitro. 2009;6;472-479.
25) Lahaie-Collins V, Bournival J, Plouffe M, Carange J, Martinoli MG. Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP- induced oxidative stress. Oxid Med Cell Longev. 2008;1;54-62.
27) Ouyang YQ, Li SJ, Zhang Q, Cai HB, Chen HP. Interactions between inflammatory and oxidative stress in preeclampsia. Hypertens Pregnancy. 2009;28;56-62.
28) Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen da C, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, Kosten TR. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology. 2009;204;177-184.
29) Murray PJ. Understanding and exploiting the endogenous interleukin- 10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006;6;379-386.
30) MK Kale, DR SN Umathe and DR KP Bhusari. Oxidative stress and the thyroid, positive health,2006,24-27
31) Ardıç F , Özgen M, Aybek H, Rota S, Çubukçu D and Gökgöz A. Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in fibromyalgia patients . Rheumatology international. 2007;27;441-446.
32) Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia — a prospective longitudinal study over 6 months. J Rheumatol. 2008;35;1366-1370.
33) Maes M , Major depression and activation of the inflammatory
response system. Adv. Exp. Med. Biol. 1999;461;25–46.
34) Geenen R, Jacobs JWG, Bijlsma JWJ. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin N Am. 2002;28;389- 404.
35) A. Gur, M. Karakoc, K. Nas, Remzi, Cevik and A. Denli. Cytokines and depression in cases with fibromyalgia, J Rheumatol. 2002;29;3558–3561.
36) Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and cytokine connection. Curr Pain Headache Rep 2003;7;342–347.
37) Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H. Detection of interleukin 1 beta (IL- 1beta), IL-6, and tumor necrosis factor- alpha in skin of patients with fibromyalgia. The Journal of Rheumatology.2003;30;146-150.
38) Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia.J Musculoskeletal Pain.1997;5;5–15.
39) Bagis S, Tamer L, Sahin G, Bilgin R, Guler H, Ercan B, Erdogan C. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 2005;25;188– 190.
40) Griffin WS, Mrak RE. IL-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease. J Leukoc Biol. 2002;72;233-238.
41) van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on IL-4, IL-10, and IL-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am. 2002;28;127-149.
42) Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S. “Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia”. Int. J. Neuropsychopharmacol. 2007;10;557– 563.
43) Chesnokova V and Melmed S. Neuro-Immuno-Endocrine Modulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis by gp130 Signaling Molecules. Endocrinology. 2002;143;1571-1574.
44) Hawley RG. Hematopathology of IL 6-type cytokines. Stem Cells. 1994;12;155-171.
45) Gruol DL, Nelson TE. Physiological and pathological roles of IL-6 in the central nervous system. Mol Neurobiol. 1997;15;307-339.
46) Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003;3;293- 298.
47) Hohmeier HE, Tran VV, Chen G, Gasa R, Newgard CB. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int J Obes Relat Metab Disord. 2003;27;6-12.
48) Halle M, Berg A, Northoff H, Keul J. Importance of TNF-α and leptin in obesity and insulin resistance: a
hypothesis on the impact of physical exercise. Exerc Immunol Rev. 1998;4;77-94.
49) Ortega E, García JJ, Bote ME, Martín-Cordero L, Escalante Y, Saavedra JM, Northoff H, Giraldo E.Exercise in fibromyalgia and related inflammatory disorders known effects and unknown chances. Exerc Immunol Rev. 2009;15;42-65.
50) Buskila, D., F. Atzeni& P.Sarzi- Puttini. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmune. 2008;8;41- 43.
51) Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S. “Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia”. Int. J. Neuropsychopharmacol. 2007;10;557– 563.
52) Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 2003;66;1403– 1408.
53) Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8:18- 30.